Bridging Bio–Nano Science and Cancer Nanomedicine

Hallmarks of Cancer: The Next Generation

Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590

The blockade of immune checkpoints in cancer immunotherapy

Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838

Cancer Genome Landscapes

Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863

Principles of nanoparticle design for overcoming biological barriers to drug delivery

Blanco, E., Shen, H., & Ferrari, M. (2015) · Nature Biotechnology · doi:10.1038/nbt.3330 · Cited by 7,002

A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs.

Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781

Cancer nanomedicine: progress, challenges and opportunities

Shi, J., Kantoff, P. W., Wooster, R., & Farokhzad, O. C. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.108 · Cited by 5,873

Analysis of nanoparticle delivery to tumours

Wilhelm, S., Tavares, A. J., Dai, Q., Ohta, S., Audet, J., Dvorak, H. F., & Chan, W. C. W. (2016) · Nature Reviews Materials · doi:10.1038/natrevmats.2016.14 · Cited by 5,218

The future of immune checkpoint therapy

Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878

Doxil® — The first FDA-approved nano-drug: Lessons learned

Barenholz, Y. (. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.020 · Cited by 4,792

Neoantigens in cancer immunotherapy

Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783

A manifesto for reproducible science

Munafò, M. R., Nosek, B. A., Bishop, D. V. M., Button, K. S., Chambers, C. D., Percie du Sert, N., Simonsohn, U., Wagenmakers, E.-J., Ware, J. J., & Ioannidis, J. P. A. (2017) · Nature Human Behaviour · doi:10.1038/s41562-016-0021 · Cited by 3,397

Cellular uptake of nanoparticles: Journey inside the cell

Behzadi, S., Serpooshan, V., Tao, W., Hamaly, M. A., Alkawareek, M. Y., Dreaden, E. C., Brown, D., Alkilany, A. M., Farokhzad, O. C., & Mahmoudi, M. (2017) · Chemical Society Reviews · doi:10.1039/c6cs00636a · Cited by 2,859

Drug penetration in solid tumours

Minchinton, A. I., & Tannock, I. F. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1893 · Cited by 2,805

Promoting an open research culture

Nosek, B. A., Alter, G., Banks, G. C., Borsboom, D., Bowman, S. D., Breckler, S. J., Buck, S., Chambers, C. D., Chin, G., Christensen, G., et al. (2015) · Science · doi:10.1126/science.aab2374 · Cited by 2,708

Influence of tumour micro-environment heterogeneity on therapeutic response

Junttila, M. R., & de Sauvage, F. J. (2013) · Nature · doi:10.1038/nature12626 · Cited by 2,694

T cell exclusion, immune privilege, and the tumor microenvironment

Joyce, J. A., & Fearon, D. T. (2015) · Science · doi:10.1126/science.aaa6204 · Cited by 2,473

Tumour heterogeneity and cancer cell plasticity

Meacham, C. E., & Morrison, S. J. (2013) · Nature · doi:10.1038/nature12624 · Cited by 2,446

PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations

Zou, W., Wolchok, J. D., & Chen, L. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad7118 · Cited by 2,400

Antibody therapy of cancer

Scott, A. M., Wolchok, J. D., & Old, L. J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3236 · Cited by 2,160

Chemotherapy and the war on cancer

Chabner, B. A., & Roberts, T. G. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1529 · Cited by 2,154

Metastatic colonization by circulating tumour cells

Massagué, J., & Obenauf, A. C. (2016) · Nature · doi:10.1038/nature17038 · Cited by 2,062

Cancer immunotherapy via dendritic cells

Palucka, K., & Banchereau, J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3258 · Cited by 2,049

A History of Cancer Chemotherapy

DeVita, V. T., & Chu, E. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6611 · Cited by 1,970

Targeted drug delivery to tumors: Myths, reality and possibility

Bae, Y. H., & Park, K. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.06.001 · Cited by 1,935

Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy

Kranz, L. M., Diken, M., Haas, H., Kreiter, S., Loquai, C., Reuter, K. C., Meng, M., Fritz, D., Vascotto, F., Hefesha, H., et al. (2016) · Nature · doi:10.1038/nature18300 · Cited by 1,819

Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYX™/Doxil®) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancer

O’Brien, M. E. R., Wigler, N., Inbar, M., Rosso, R., Grischke, E., Santoro, A., Catane, R., Kieback, D. G., Tomczak, P., Ackland, S. P., et al. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh097 · Cited by 1,738

Image-based analysis of lipid nanoparticle–mediated siRNA delivery, intracellular trafficking and endosomal escape

Gilleron, J., Querbes, W., Zeigerer, A., Borodovsky, A., Marsico, G., Schubert, U., Manygoats, K., Seifert, S., Andree, C., Stöter, M., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2612 · Cited by 1,681

Technology-driven layer-by-layer assembly of nanofilms

Richardson, J. J., Björnmalm, M., & Caruso, F. (2015) · Science · doi:10.1126/science.aaa2491 · Cited by 1,641

Photothermal therapy with immune-adjuvant nanoparticles together with checkpoint blockade for effective cancer immunotherapy

Chen, Q., Xu, L., Liang, C., Wang, C., Peng, R., & Liu, Z. (2016) · Nature Communications · doi:10.1038/ncomms13193 · Cited by 1,596

Challenges and Key Considerations of the Enhanced Permeability and Retention Effect for Nanomedicine Drug Delivery in Oncology

Prabhakar, U., Maeda, H., Jain, R. K., Sevick-Muraca, E. M., Zamboni, W., Farokhzad, O. C., Barry, S. T., Gabizon, A., Grodzinski, P., & Blakey, D. C. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4561 · Cited by 1,485

Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies

Naidoo, J., Page, D. B., Li, B. T., Connell, L. C., Schindler, K., Lacouture, M. E., Postow, M. A., & Wolchok, J. D. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv383 · Cited by 1,470

Can Animal Models of Disease Reliably Inform Human Studies?

van der Worp, H. B., Howells, D. W., Sena, E. S., Porritt, M. J., Rewell, S., O'Collins, V., & Macleod, M. R. (2010) · PLoS Medicine · doi:10.1371/journal.pmed.1000245 · Cited by 1,354

Diverse Applications of Nanomedicine

Pelaz, B., Alexiou, C., Alvarez-Puebla, R. A., Alves, F., Andrews, A. M., Ashraf, S., Balogh, L. P., Ballerini, L., Bestetti, A., Brendel, C., et al. (2017) · ACS Nano · doi:10.1021/acsnano.6b06040 · Cited by 1,350

Epigenetic plasticity and the hallmarks of cancer

Flavahan, W. A., Gaskell, E., & Bernstein, B. E. (2017) · Science · doi:10.1126/science.aal2380 · Cited by 1,340

Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy

Pitt, J. M., Marabelle, A., Eggermont, A., Soria, J.-C., Kroemer, G., & Zitvogel, L. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw168 · Cited by 1,338

Drug targeting to tumors: Principles, pitfalls and (pre-) clinical progress

Lammers, T., Kiessling, F., Hennink, W. E., & Storm, G. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.09.063 · Cited by 1,324

Multifunctional Nanoparticles: Cost Versus Benefit of Adding Targeting and Imaging Capabilities

Cheng, Z., Al Zaki, A., Hui, J. Z., Muzykantov, V. R., & Tsourkas, A. (2012) · Science · doi:10.1126/science.1226338 · Cited by 1,322

To exploit the tumor microenvironment: Since the EPR effect fails in the clinic, what is the future of nanomedicine?

Danhier, F. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.11.015 · Cited by 1,288

Nanomaterials for Theranostics: Recent Advances and Future Challenges

Lim, E.-K., Kim, T., Paik, S., Haam, S., Huh, Y.-M., & Lee, K. (2015) · Chemical Reviews · doi:10.1021/cr300213b · Cited by 1,233

Challenges and strategies in anti-cancer nanomedicine development: An industry perspective

Hare, J. I., Lammers, T., Ashford, M. B., Puri, S., Storm, G., & Barry, S. T. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.04.025 · Cited by 1,214

Tumour heterogeneity in the clinic

Bedard, P. L., Hansen, A. R., Ratain, M. J., & Siu, L. L. (2013) · Nature · doi:10.1038/nature12627 · Cited by 1,211

Organs-on-chips at the frontiers of drug discovery

Esch, E. W., Bahinski, A., & Huh, D. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4539 · Cited by 1,185

Gold Nanomaterials at Work in Biomedicine

Yang, X., Yang, M., Pang, B., Vara, M., & Xia, Y. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00193 · Cited by 1,162

Treating metastatic cancer with nanotechnology

Schroeder, A., Heller, D. A., Winslow, M. M., Dahlman, J. E., Pratt, G. W., Langer, R., Jacks, T., & Anderson, D. G. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3180 · Cited by 1,159

Nanomedicine

Kim, B. Y. S., Rutka, J. T., & Chan, W. C. W. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0912273 · Cited by 1,147

Tissue-Penetrating Delivery of Compounds and Nanoparticles into Tumors

Sugahara, K. N., Teesalu, T., Karmali, P. P., Kotamraju, V. R., Agemy, L., Girard, O. M., Hanahan, D., Mattrey, R. F., & Ruoslahti, E. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.10.013 · Cited by 1,136

Antibody Targeting of Long-Circulating Lipidic Nanoparticles Does Not Increase Tumor Localization but Does Increase Internalization in Animal Models

Kirpotin, D. B., Drummond, D. C., Shao, Y., Shalaby, M. R., Hong, K., Nielsen, U. B., Marks, J. D., Benz, C. C., & Park, J. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4199 · Cited by 1,125

Rethinking cancer nanotheranostics

Chen, H., Zhang, W., Zhu, G., Xie, J., & Chen, X. (2017) · Nature Reviews Materials · doi:10.1038/natrevmats.2017.24 · Cited by 1,102

Nanodrug Delivery: Is the Enhanced Permeability and Retention Effect Sufficient for Curing Cancer?

Nakamura, Y., Mochida, A., Choyke, P. L., & Kobayashi, H. (2016) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.6b00437 · Cited by 1,101

Coadministration of a Tumor-Penetrating Peptide Enhances the Efficacy of Cancer Drugs

Sugahara, K. N., Teesalu, T., Karmali, P. P., Kotamraju, V. R., Agemy, L., Greenwald, D. R., & Ruoslahti, E. (2010) · Science · doi:10.1126/science.1183057 · Cited by 1,075

Nanomaterials for In Vivo Imaging

Smith, B. R., & Gambhir, S. S. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00073 · Cited by 1,075

Multistage nanoparticle delivery system for deep penetration into tumor tissue

Wong, C., Stylianopoulos, T., Cui, J., Martin, J., Chauhan, V. P., Jiang, W., Popović, Z., Jain, R. K., Bawendi, M. G., & Fukumura, D. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1018382108 · Cited by 1,062

Rational Design of Cancer Nanomedicine: Nanoproperty Integration and Synchronization

Sun, Q., Zhou, Z., Qiu, N., & Shen, Y. (2017) · Advanced Materials · doi:10.1002/adma.201606628 · Cited by 1,058

Lost in translation: animal models and clinical trials in cancer treatment.

(2014) · Europe PMC (PubMed Central) · Cited by 1,033

Mechanism of hard-nanomaterial clearance by the liver

Tsoi, K. M., MacParland, S. A., Ma, X.-Z., Spetzler, V. N., Echeverri, J., Ouyang, B., Fadel, S. M., Sykes, E. A., Goldaracena, N., Kaths, J. M., et al. (2016) · Nature Materials · doi:10.1038/nmat4718 · Cited by 1,010

Simultaneous PET-MRI: a new approach for functional and morphological imaging

Judenhofer, M. S., Wehrl, H. F., Newport, D. F., Catana, C., Siegel, S. B., Becker, M., Thielscher, A., Kneilling, M., Lichy, M. P., Eichner, M., et al. (2008) · Nature Medicine · doi:10.1038/nm1700 · Cited by 981

Systemic Immunity Is Required for Effective Cancer Immunotherapy

Spitzer, M. H., Carmi, Y., Reticker-Flynn, N. E., Kwek, S. S., Madhireddy, D., Martins, M. M., Gherardini, P. F., Prestwood, T. R., Chabon, J., Bendall, S. C., et al. (2017) · Cell · doi:10.1016/j.cell.2016.12.022 · Cited by 963

Neutrophil-mediated anticancer drug delivery for suppression of postoperative malignant glioma recurrence

Xue, J., Zhao, Z., Zhang, L., Xue, L., Shen, S., Wen, Y., Wei, Z., Wang, L., Kong, L., Sun, H., et al. (2017) · Nature Nanotechnology · doi:10.1038/nnano.2017.54 · Cited by 959

Efficiency of siRNA delivery by lipid nanoparticles is limited by endocytic recycling

Sahay, G., Querbes, W., Alabi, C., Eltoukhy, A., Sarkar, S., Zurenko, C., Karagiannis, E., Love, K., Chen, D., Zoncu, R., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2614 · Cited by 948

Combination cancer immunotherapies tailored to the tumour microenvironment

Smyth, M. J., Ngiow, S. F., Ribas, A., & Teng, M. W. L. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.209 · Cited by 944

Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine

Pauli, C., Hopkins, B. D., Prandi, D., Shaw, R., Fedrizzi, T., Sboner, A., Sailer, V., Augello, M., Puca, L., Rosati, R., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1154 · Cited by 937

Nanoparticle design strategies for enhanced anticancer therapy by exploiting the tumour microenvironment

Dai, Y., Xu, C., Sun, X., & Chen, X. (2017) · Chemical Society Reviews · doi:10.1039/c6cs00592f · Cited by 931

The future of cancer treatment: immunomodulation, CARs and combination immunotherapy

Khalil, D. N., Smith, E. L., Brentjens, R. J., & Wolchok, J. D. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.25 · Cited by 929

Innovation in Layer-by-Layer Assembly

Richardson, J. J., Cui, J., Björnmalm, M., Braunger, J. A., Ejima, H., & Caruso, F. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00627 · Cited by 922

A STING-activating nanovaccine for cancer immunotherapy

Luo, M., Wang, H., Wang, Z., Cai, H., Lu, Z., Li, Y., Du, M., Huang, G., Wang, C., Chen, X., et al. (2017) · Nature Nanotechnology · doi:10.1038/nnano.2017.52 · Cited by 900

Clearance Pathways and Tumor Targeting of Imaging Nanoparticles

Yu, M., & Zheng, J. (2015) · ACS Nano · doi:10.1021/acsnano.5b01320 · Cited by 886

Therapeutic T cell engineering

Sadelain, M., Rivière, I., & Riddell, S. (2017) · Nature · doi:10.1038/nature22395 · Cited by 879

Size-Dependent Localization and Penetration of Ultrasmall Gold Nanoparticles in Cancer Cells, Multicellular Spheroids, and Tumors in Vivo

Huang, K., Ma, H., Liu, J., Huo, S., Kumar, A., Wei, T., Zhang, X., Jin, S., Gan, Y., Wang, P. C., et al. (2012) · ACS Nano · doi:10.1021/nn301282m · Cited by 840

EPR: Evidence and fallacy

Nichols, J. W., & Bae, Y. H. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.03.057 · Cited by 834

Targeted Cancer Therapy: Conferring Specificity to Cytotoxic Drugs

Chari, R. V. J. (2008) · Accounts of Chemical Research · doi:10.1021/ar700108g · Cited by 815

Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging

Bartlett, D. W., Su, H., Hildebrandt, I. J., Weber, W. A., & Davis, M. E. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707461104 · Cited by 803

In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers

Smith, T. T., Stephan, S. B., Moffett, H. F., McKnight, L. E., Ji, W., Reiman, D., Bonagofski, E., Wohlfahrt, M. E., Pillai, S. P. S., & Stephan, M. T. (2017) · Nature Nanotechnology · doi:10.1038/nnano.2017.57 · Cited by 785

Degradability and Clearance of Silicon, Organosilica, Silsesquioxane, Silica Mixed Oxide, and Mesoporous Silica Nanoparticles

Croissant, J. G., Fatieiev, Y., & Khashab, N. M. (2017) · Advanced Materials · doi:10.1002/adma.201604634 · Cited by 782

Applications of nanotechnology for immunology

Smith, D. M., Simon, J. K., & Baker Jr, J. R. (2013) · Nature Reviews Immunology · doi:10.1038/nri3488 · Cited by 767

Synthetic Nanoparticles for Vaccines and Immunotherapy

Irvine, D. J., Hanson, M. C., Rakhra, K., & Tokatlian, T. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00109 · Cited by 763

Toward understanding and exploiting tumor heterogeneity

Alizadeh, A. A., Aranda, V., Bardelli, A., Blanpain, C., Bock, C., Borowski, C., Caldas, C., Califano, A., Doherty, M., Elsner, M., et al. (2015) · Nature Medicine · doi:10.1038/nm.3915 · Cited by 746

Stimuli-responsive clustered nanoparticles for improved tumor penetration and therapeutic efficacy

Li, H.-J., Du, J.-Z., Du, X.-J., Xu, C.-F., Sun, C.-Y., Wang, H.-X., Cao, Z.-T., Yang, X.-Z., Zhu, Y.-H., Nie, S., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1522080113 · Cited by 724

Building better monoclonal antibody-based therapeutics

Weiner, G. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3930 · Cited by 712

Clinical translation of an ultrasmall inorganic optical-PET imaging nanoparticle probe

Phillips, E., Penate-Medina, O., Zanzonico, P. B., Carvajal, R. D., Mohan, P., Ye, Y., Humm, J., Gönen, M., Kalaigian, H., Schöder, H., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009524 · Cited by 712

Vaccines for established cancer: overcoming the challenges posed by immune evasion

van der Burg, S. H., Arens, R., Ossendorp, F., van Hall, T., & Melief, C. J. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.16 · Cited by 709

Antigen-capturing nanoparticles improve the abscopal effect and cancer immunotherapy

Min, Y., Roche, K. C., Tian, S., Eblan, M. J., McKinnon, K. P., Caster, J. M., Chai, S., Herring, L. E., Zhang, L., Zhang, T., et al. (2017) · Nature Nanotechnology · doi:10.1038/nnano.2017.113 · Cited by 701

Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles

Choi, C. H. J., Alabi, C. A., Webster, P., & Davis, M. E. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914140107 · Cited by 699

Synergistically Integrated Nanoparticles as Multimodal Probes for Nanobiotechnology

Cheon, J., & Lee, J.-H. (2008) · Accounts of Chemical Research · doi:10.1021/ar800045c · Cited by 683

Translation of new cancer treatments from pet dogs to humans

Paoloni, M., & Khanna, C. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2273 · Cited by 668

Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial.

Northfelt, D. W., Dezube, B. J., Thommes, J. A., Miller, B. J., Fischl, M. A., Friedman-Kien, A., Kaplan, L. D., Du Mond, C., Mamelok, R. D., & Henry, D. H. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.7.2445 · Cited by 649

The mononuclear phagocyte system

Hume, D. A. (2006) · Current Opinion in Immunology · doi:10.1016/j.coi.2005.11.008 · Cited by 649

Investigating the Impact of Nanoparticle Size on Active and Passive Tumor Targeting Efficiency

Sykes, E. A., Chen, J., Zheng, G., & Chan, W. C. W. (2014) · ACS Nano · doi:10.1021/nn500299p · Cited by 635

Antibody tumor penetration: Transport opposed by systemic and antigen-mediated clearance

Thurber, G. M., Schmidt, M. M., & Wittrup, K. D. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.04.012 · Cited by 624

Microvascular permeability of normal and neoplastic tissues

Gerlowski, L. E., & Jain, R. K. (1986) · Microvascular Research · doi:10.1016/0026-2862(86)90018-x · Cited by 622

Antibody–drug conjugates for cancer therapy

Thomas, A., Teicher, B. A., & Hassan, R. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30030-4 · Cited by 606

A modeling analysis of the effects of molecular size and binding affinity on tumor targeting

Schmidt, M. M., & Wittrup, K. D. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0195 · Cited by 576

Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes.

Harrington, K. J., Mohammadtaghi, S., Uster, P. S., Glass, D. M., Peters, A. M., Vile, R. G., & Stewart, J. S. W. (2001) · PubMed · Cited by 575

Facing the Truth about Nanotechnology in Drug Delivery

Park, K. (2013) · ACS Nano · doi:10.1021/nn404501g · Cited by 544

Antibody Therapeutics in Cancer

Sliwkowski, M. X., & Mellman, I. (2013) · Science · doi:10.1126/science.1241145 · Cited by 543

Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses

Moynihan, K. D., Opel, C. F., Szeto, G. L., Tzeng, A., Zhu, E. F., Engreitz, J. M., Williams, R. T., Rakhra, K., Zhang, M. H., Rothschilds, A. M., et al. (2016) · Nature Medicine · doi:10.1038/nm.4200 · Cited by 524

A multifunctional core–shell nanoparticle for dendritic cell-based cancer immunotherapy

Cho, N.-H., Cheong, T.-C., Min, J. H., Wu, J. H., Lee, S. J., Kim, D., Yang, J.-S., Kim, S., Kim, Y. K., & Seong, S.-Y. (2011) · Nature Nanotechnology · doi:10.1038/nnano.2011.149 · Cited by 514

The distribution of the anticancer drug Doxorubicin in relation to blood vessels in solid tumors

Primeau, A. J., Rendon, A., Hedley, D., Lilge, L., & Tannock, I. F. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1664 · Cited by 499

Combination delivery of TGF-β inhibitor and IL-2 by nanoscale liposomal polymeric gels enhances tumour immunotherapy

Park, J., Wrzesinski, S. H., Stern, E., Look, M., Criscione, J., Ragheb, R., Jay, S. M., Demento, S. L., Agawu, A., Licona Limon, P., et al. (2012) · Nature Materials · doi:10.1038/nmat3355 · Cited by 494

Vascular and interstitial barriers to delivery of therapeutic agents in tumors

Jain, R. K. (1990) · CANCER AND METASTASIS REVIEW · doi:10.1007/bf00046364 · Cited by 489

In situ vaccination with cowpea mosaic virus nanoparticles suppresses metastatic cancer

Lizotte, P. H., Wen, A. M., Sheen, M. R., Fields, J., Rojanasopondist, P., Steinmetz, N. F., & Fiering, S. (2016) · Nature Nanotechnology · doi:10.1038/nnano.2015.292 · Cited by 485

A holistic approach to targeting disease with polymeric nanoparticles

Cheng, C. J., Tietjen, G. T., Saucier-Sawyer, J. K., & Saltzman, W. M. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4503 · Cited by 480

Noninvasive Imaging of Nanomedicines and Nanotheranostics: Principles, Progress, and Prospects

Kunjachan, S., Ehling, J., Storm, G., Kiessling, F., & Lammers, T. (2015) · Chemical Reviews · doi:10.1021/cr500314d · Cited by 480

Nanoparticle-Based Immunotherapy for Cancer

Shao, K., Singha, S., Clemente-Casares, X., Tsai, S., Yang, Y., & Santamaria, P. (2015) · ACS Nano · doi:10.1021/nn5062029 · Cited by 470

Cell membrane-derived nanomaterials for biomedical applications

Fang, R. H., Jiang, Y., Fang, J. C., & Zhang, L. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.02.041 · Cited by 468

Tumor-Penetrating Nanoparticles for Enhanced Anticancer Activity of Combined Photodynamic and Hypoxia-Activated Therapy

Wang, Y., Xie, Y., Li, J., Peng, Z.-H., Sheinin, Y., Zhou, J., & Oupický, D. (2017) · ACS Nano · doi:10.1021/acsnano.6b08731 · Cited by 461

Tumor penetrating peptides for improved drug delivery

Ruoslahti, E. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.03.008 · Cited by 459

Tumour‐associated macrophages act as a slow‐release reservoir of nano‐therapeutic Pt(IV) pro‐drug

Miller, M. A., Zheng, Y.-R., Gadde, S., Pfirschke, C., Zope, H., Engblom, C., Kohler, R. H., Iwamoto, Y., Yang, K. S., Askevold, B., et al. (2015) · Nature Communications · doi:10.1038/ncomms9692 · Cited by 441

Phase I Study of 68Ga-HER2-Nanobody for PET/CT Assessment of HER2 Expression in Breast Carcinoma

Keyaerts, M., Xavier, C., Heemskerk, J., Devoogdt, N., Everaert, H., Ackaert, C., Vanhoeij, M., Duhoux, F. P., Gevaert, T., Simon, P., et al. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.162024 · Cited by 429

A Reexamination of Active and Passive Tumor Targeting by Using Rod-Shaped Gold Nanocrystals and Covalently Conjugated Peptide Ligands

Huang, X., Peng, X., Wang, Y., Wang, Y., Shin, D. M., El-Sayed, M. A., & Nie, S. (2010) · ACS Nano · doi:10.1021/nn102055s · Cited by 427

Correlating animal and human phase Ia/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA

Zuckerman, J. E., Gritli, I., Tolcher, A., Heidel, J. D., Lim, D., Morgan, R., Chmielowski, B., Ribas, A., Davis, M. E., & Yen, Y. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1411393111 · Cited by 427

Biomaterials and emerging anticancer therapeutics: engineering the microenvironment

Gu, L., & Mooney, D. J. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2015.3 · Cited by 407

Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier.

Juweid, M. E., Neumann, R. D., Paik, C. H., Pérez-Bacete, M., Sato, J., van Osdol, W. W., & Weinstein, J. N. (1992) · PubMed · Cited by 406

Analysis on the current status of targeted drug delivery to tumors

Kwon, I. K., Lee, S. C., Han, B., & Park, K. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.07.010 · Cited by 404

Mouse models of advanced spontaneous metastasis for experimental therapeutics

Francia, G., Cruz-Munoz, W., Man, S., Xu, P., & Kerbel, R. S. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3001 · Cited by 374

Odyssey of a cancer nanoparticle: From injection site to site of action

Nichols, J. W., & Bae, Y. H. (2012) · Nano Today · doi:10.1016/j.nantod.2012.10.010 · Cited by 364

Recent advances in the construction of antibody–drug conjugates

Chudasama, V., Maruani, A., & Caddick, S. (2016) · Nature Chemistry · doi:10.1038/nchem.2415 · Cited by 352

The effects of particle size and molecular targeting on the intratumoral and subcellular distribution of polymeric nanoparticles

Lee, H., Fonge, H., Hoang, B., Reilly, R. M., & Allen, C. (2010) · Molecular Pharmaceutics · doi:10.1021/mp100038h · Cited by 349

Does a targeting ligand influence nanoparticle tumor localization or uptake?

Pirollo, K. F., & Chang, E. H. (2008) · Trends in Biotechnology · doi:10.1016/j.tibtech.2008.06.007 · Cited by 347

Alpha-alumina nanoparticles induce efficient autophagy-dependent cross-presentation and potent antitumour response

Li, H., Li, Y., Jiao, J., & Hu, H.-M. (2011) · Nature Nanotechnology · doi:10.1038/nnano.2011.153 · Cited by 347

Predicting therapeutic nanomedicine efficacy using a companion magnetic resonance imaging nanoparticle

Miller, M. A., Gadde, S., Pfirschke, C., Engblom, C., Sprachman, M. M., Kohler, R. H., Yang, K. S., Laughney, A. M., Wojtkiewicz, G., Kamaly, N., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac6522 · Cited by 347

Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors

Schütte, M., Risch, T., Abdavi-Azar, N., Boehnke, K., Schumacher, D., Keil, M., Yildiriman, R., Jandrasits, C., Borodina, T., Amstislavskiy, V., et al. (2017) · Nature Communications · doi:10.1038/ncomms14262 · Cited by 339

Mechanisms and Barriers in Cancer Nanomedicine: Addressing Challenges, Looking for Solutions

Anchordoquy, T. J., Barenholz, Y., Boraschi, D., Chorny, M., Decuzzi, P., Dobrovolskaia, M. A., Farhangrazi, Z. S., Farrell, D., Gabizon, A., Ghandehari, H., et al. (2017) · ACS Nano · doi:10.1021/acsnano.6b08244 · Cited by 337

Evolution of the nanoparticle corona

Hadjidemetriou, M., & Kostarelos, K. (2017) · Nature Nanotechnology · doi:10.1038/nnano.2017.61 · Cited by 336

Doxorubicin as a Molecular Nanotheranostic Agent: Effect of Doxorubicin Encapsulation in Micelles or Nanoemulsions on the Ultrasound-Mediated Intracellular Delivery and Nuclear Trafficking

Mohan, P., & Rapoport, N. (2010) · Molecular Pharmaceutics · doi:10.1021/mp100269f · Cited by 331

Tumour-on-a-chip provides an optical window into nanoparticle tissue transport

Albanese, A., Lam, A. K., Sykes, E. A., Rocheleau, J. V., & Chan, W. C. W. (2013) · Nature Communications · doi:10.1038/ncomms3718 · Cited by 330

Breaking Down the Barriers to Precision Cancer Nanomedicine

von Roemeling, C., Jiang, W., Chan, C. K., Weissman, I. L., & Kim, B. Y. S. (2017) · Trends in Biotechnology · doi:10.1016/j.tibtech.2016.07.006 · Cited by 330

Passive versus Active Tumor Targeting Using RGD- and NGR-Modified Polymeric Nanomedicines

Kunjachan, S., Pola, R., Gremse, F., Theek, B., Ehling, J., Moeckel, D., Hermanns-Sachweh, B., Pechar, M., Ulbrich, K., Hennink, W. E., et al. (2014) · Nano Letters · doi:10.1021/nl404391r · Cited by 317

Lipid-based nanovesicles for nanomedicine

Grimaldi, N., Andrade, F., Segovia, N., Ferrer-Tasies, L., Sala, S., Veciana, J., & Ventosa, N. (2016) · Chemical Society Reviews · doi:10.1039/c6cs00409a · Cited by 309

Delivering safer immunotherapies for cancer

Milling, L., Zhang, Y., & Irvine, D. J. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.05.011 · Cited by 305

Coming Full Circle—From Endless Complexity to Simplicity and Back Again

Weinberg, R. A. (2014) · Cell · doi:10.1016/j.cell.2014.03.004 · Cited by 294

Meta-analysis of clinical and preclinical studies comparing the anticancer efficacy of liposomal versus conventional non-liposomal doxorubicin

Petersen, G. H., Alzghari, S. K., Chee, W., Sankari, S. S., & La-Beck, N. M. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.04.028 · Cited by 290

Tailoring Biomaterials for Cancer Immunotherapy: Emerging Trends and Future Outlook

Wang, C., Ye, Y., Hu, Q., Bellotti, A., & Gu, Z. (2017) · Advanced Materials · doi:10.1002/adma.201606036 · Cited by 286

Selected Standard Protocols for the Synthesis, Phase Transfer, and Characterization of Inorganic Colloidal Nanoparticles

Hühn, J., Carrillo-Carrion, C., Soliman, M. G., Pfeiffer, C., Valdeperez, D., Masood, A., Chakraborty, I., Zhu, L., Gallego, M., Yue, Z., et al. (2017) · Chemistry of Materials · doi:10.1021/acs.chemmater.6b04738 · Cited by 283

Tailoring nanoparticle designs to target cancer based on tumor pathophysiology

Sykes, E. A., Dai, Q., Sarsons, C. D., Chen, J., Rocheleau, J. V., Hwang, D. M., Zheng, G., Cramb, D. T., Rinker, K. D., & Chan, W. C. W. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1521265113 · Cited by 281

Design considerations for nanotherapeutics in oncology

Stylianopoulos, T., & Jain, R. K. (2015) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2015.07.015 · Cited by 280

An injectable nanoparticle generator enhances delivery of cancer therapeutics

Xu, R., Zhang, G., Mai, J., Deng, X., Segura-Ibarra, V., Wu, S., Shen, J., Liu, H., Hu, Z., Chen, L., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3506 · Cited by 280

Immunoengineering: How Nanotechnology Can Enhance Cancer Immunotherapy

Goldberg, M. S. (2015) · Cell · doi:10.1016/j.cell.2015.03.037 · Cited by 278

Positron Emission Tomography Based Elucidation of the Enhanced Permeability and Retention Effect in Dogs with Cancer Using Copper-64 Liposomes

Hansen, A. E., Petersen, A. L., Henriksen, J. R., Boerresen, B., Rasmussen, P., Elema, D. R., Rosenschöld, P. M. A., Kristensen, A. T., Kjær, A., & Andresen, T. L. (2015) · ACS Nano · doi:10.1021/acsnano.5b01324 · Cited by 277

Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody.

Press, O. W., Eary, J. F., Badger, C. C., Martin, P. J., Appelbaum, F. R., Levy, R., Miller, R., Brown, S., Nelp, W. B., & Krohn, K. A. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.8.1027 · Cited by 274

First-in-Human Molecular Imaging of HER2 Expression in Breast Cancer Metastases Using the 111In-ABY-025 Affibody Molecule

Sörensen, J., Sandberg, D., Sandström, M., Wennborg, A., Feldwisch, J., Tolmachev, V., Åström, G., Lubberink, M., Garske-Román, U., Carlsson, J., et al. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.113.131243 · Cited by 258

Liposomal Delivery Enhances Immune Activation by STING Agonists for Cancer Immunotherapy

Koshy, S. T., Cheung, A. S., Gu, L., Graveline, A. R., & Mooney, D. J. (2017) · Advanced Biosystems · doi:10.1002/adbi.201600013 · Cited by 256

Tumor-targeted nanomedicines for cancer theranostics

Arranja, A., Pathak, V., Lammers, T., & Shi, Y. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.11.014 · Cited by 249

Identification of Receptor Binding to the Biomolecular Corona of Nanoparticles

Lara, S., Alnasser, F., Polo, E., Garry, D., Lo Giudice, M. C., Hristov, D. R., Rocks, L., Salvati, A., Yan, Y., & Dawson, K. A. (2017) · ACS Nano · doi:10.1021/acsnano.6b07933 · Cited by 243

DARPins and other repeat protein scaffolds: advances in engineering and applications

Boersma, Y. L., & Plückthun, A. (2011) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2011.06.004 · Cited by 239

Comparison of active, passive and magnetic targeting to tumors of multifunctional paclitaxel/SPIO-loaded nanoparticles for tumor imaging and therapy

Schleich, N., Po, C., Jacobs, D., Ucakar, B., Gallez, B., Danhier, F., & Préat, V. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.07.059 · Cited by 238

Nanomedicine strategies to overcome the pathophysiological barriers of pancreatic cancer

Adiseshaiah, P. P., Crist, R. M., Hook, S. S., & McNeil, S. E. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.119 · Cited by 238

Cancer nanomedicine: is targeting our target?

Lammers, T., Kiessling, F. M., Ashford, M. B., Hennink, W. E., Crommelin, D. J. A., & Storm, G. (2016) · Nature Reviews Materials · doi:10.1038/natrevmats.2016.69 · Cited by 234

Phenotype Determines Nanoparticle Uptake by Human Macrophages from Liver and Blood

MacParland, S. A., Tsoi, K. M., Ouyang, B., Ma, X., Manuel, J., Fawaz, A., Ostrowski, M., Alman, B. A., Zilman, A., Chan, W. C. W., et al. (2016) · ACS Nano · doi:10.1021/acsnano.6b06245 · Cited by 233

Development of next-generation macromolecular drugs based on the EPR effect: challenges and pitfalls

Nakamura, H., Jun, F., & Maeda, H. (2015) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.955011 · Cited by 232

Designing nanomedicine for immuno-oncology

Jiang, W., Roemeling, C. A. V., Chen, Y., Qie, Y., Liu, X., Chen, J., & Kim, B. Y. S. (2017) · Nature Biomedical Engineering · doi:10.1038/s41551-017-0029 · Cited by 232

Radiation therapy primes tumors for nanotherapeutic delivery via macrophage-mediated vascular bursts

Miller, M. A., Chandra, R., Cuccarese, M. F., Pfirschke, C., Engblom, C., Stapleton, S., Adhikary, U., Kohler, R. H., Mohan, J. F., Pittet, M. J., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal0225 · Cited by 225

A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclide.

Scheinberg, D. A., Lovett, D., Divgi, C. R., Graham, M. C., Berman, E., Pentlow, K., Feirt, N., Finn, R. D., Clarkson, B. D., & Gee, T. S. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.3.478 · Cited by 224

A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors

Scott, A. M., Lee, F.-T., Tebbutt, N., Herbertson, R., Gill, S. S., Liu, Z., Skrinos, E., Murone, C., Saunder, T. H., Chappell, B., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611693104 · Cited by 222

The Binding Site Barrier Elicited by Tumor-Associated Fibroblasts Interferes Disposition of Nanoparticles in Stroma-Vessel Type Tumors

Miao, L., Newby, J. M., Lin, C. M., Zhang, L., Xu, F., Kim, W. Y., Forest, M. G., Lai, S. K., Milowsky, M. I., Wobker, S. E., et al. (2016) · ACS Nano · doi:10.1021/acsnano.6b02776 · Cited by 221

Multistage Nanovectors: From Concept to Novel Imaging Contrast Agents and Therapeutics

Godin, B., Tasciotti, E., Liu, X., Serda, R. E., & Ferrari, M. (2011) · Accounts of Chemical Research · doi:10.1021/ar200077p · Cited by 211

Reinventing Chemistry

Whitesides, G. M. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201410884 · Cited by 210

Immunological Principles Guiding the Rational Design of Particles for Vaccine Delivery

Gause, K. T., Wheatley, A. K., Cui, J., Yan, Y., Kent, S. J., & Caruso, F. (2017) · ACS Nano · doi:10.1021/acsnano.6b07343 · Cited by 202

Multicellular tumor spheroids: a relevant 3D model for the in vitro preclinical investigation of polymer nanomedicines

Lazzari, G., Couvreur, P., & Mura, S. (2017) · Polymer Chemistry · doi:10.1039/c7py00559h · Cited by 200

Assembly of Layer-by-Layer Particles and Their Interactions with Biological Systems

Yan, Y., Björnmalm, M., & Caruso, F. (2014) · Chemistry of Materials · doi:10.1021/cm402126n · Cited by 199

Enhancing tumor penetration of nanomedicines

Sun, Q., Ojha, T., Kiessling, F., Lammers, T., & Shi, Y. (2017) · Biomacromolecules · doi:10.1021/acs.biomac.7b00068 · Cited by 198

Bioprinting towards physiologically relevant tissue models for pharmaceutics

Peng, W., Unutmaz, D., & Ozbolat, I. T. (2016) · Trends in Biotechnology · doi:10.1016/j.tibtech.2016.05.013 · Cited by 196

Kupffer Cell Metabolism and Function.

Nguyen‐Lefebvre, A. T., & Horuzsko, A. (2015) · PubMed · Cited by 195

“Targeting” nanoparticles: The constraints of physical laws and physical barriers

Florence, A. T. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.022 · Cited by 184

On the Access of Blood-Borne Dyes to Various Tumour Regions

Goldacre, R. J., & Sylvén, B. (1962) · British Journal of Cancer · doi:10.1038/bjc.1962.36 · Cited by 183

Tumor stroma-containing 3D spheroid arrays: A tool to study nanoparticle penetration

Priwitaningrum, D. L., Blondé, J.-B., Sridhar, A., van Baarlen, J., Hennink, W. E., Storm, G., Gac, S. L., & Prakash, J. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.09.004 · Cited by 174

CRLX101 nanoparticles localize in human tumors and not in adjacent, nonneoplastic tissue after intravenous dosing

Clark, A. J., Wiley, D. T., Zuckerman, J. E., Webster, P. C., Chao, J., Lin, J. L., Yen, Y., & Davis, M. E. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1603018113 · Cited by 172

Dual Targeting Nanoparticle Stimulates the Immune System To Inhibit Tumor Growth

Kosmides, A. K., Sidhom, J.-W., Fraser, A., Bessell, C. A., & Schneck, J. P. (2017) · ACS Nano · doi:10.1021/acsnano.6b08152 · Cited by 170

Effect of shape, size, and aspect ratio on nanoparticle penetration and distribution inside solid tissues using 3D spheroid models

Agarwal, R., Jurney, P., Raythatha, M., Singh, V., Sreenivasan, S. V., Shi, L., & Roy, K. (2015) · Advanced Healthcare Materials · doi:10.1002/adhm.201500441 · Cited by 169

Non-invasive mapping of deep-tissue lymph nodes in live animals using a multimodal PET/MRI nanoparticle

Thorek, D. L. J., Ulmert, D., Diop, N.-F. M., Lupu, M. E., Doran, M. G., Huang, R., Abou, D. S., Larson, S. M., & Grimm, J. (2014) · Nature Communications · doi:10.1038/ncomms4097 · Cited by 164

Nanomedicines for cancer therapy: state-of-the-art and limitations to pre-clinical studies that hinder future developments

Dawidczyk, C. M., Russell, L. M., & Searson, P. C. (2014) · Frontiers in Chemistry · doi:10.3389/fchem.2014.00069 · Cited by 164

Does Nanomedicine Have a Delivery Problem?

Torrice, M. (2016) · ACS Central Science · doi:10.1021/acscentsci.6b00190 · Cited by 163

Tumor Microenvironment-Mediated Construction and Deconstruction of Extracellular Drug-Delivery Depots

Hu, Q., Sun, W., Lu, Y., Bomba, H. N., Ye, Y., Jiang, T., Isaacson, A. J., & Gu, Z. (2016) · Nano Letters · doi:10.1021/acs.nanolett.5b04343 · Cited by 162

Cancer nanomedicines: oversold or underappreciated?

van der Meel, R., Lammers, T., & Hennink, W. E. (2016) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2017.1262346 · Cited by 156

Engineering Polymer Hydrogel Nanoparticles for Lymph Node‐Targeted Delivery

Koker, S. D., Cui, J., Vanparijs, N., Albertazzi, L., Grooten, J., Caruso, F., & Geest, B. G. D. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201508626 · Cited by 154

Tumour homing and therapeutic effect of colloidal nanoparticles depend on the number of attached antibodies

Colombo, M., Fiandra, L., Alessio, G., Mazzucchelli, S., Nebuloni, M., Palma, C. D., Kantner, K., Pelaz, B., Rotem, R., Corsi, F., et al. (2016) · Nature Communications · doi:10.1038/ncomms13818 · Cited by 150

Theranostic barcoded nanoparticles for personalized cancer medicine

Yaari, Z. A., da Silva, D., Zinger, A., Goldman, E., Kajal, A., Tshuva, R., Barak, E., Dahan, N., Hershkovitz, D., Goldfeder, M., et al. (2016) · Nature Communications · doi:10.1038/ncomms13325 · Cited by 149

Parameters Affecting the Enhanced Permeability and Retention Effect: The Need for Patient Selection

Natfji, A. A., Ravishankar, D., Osborn, H. M. I., & Greco, F. (2017) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2017.06.019 · Cited by 148

Perspectives from man’s best friend: National Academy of Medicine’s Workshop on Comparative Oncology

LeBlanc, A. K., Breen, M., Choyke, P., Dewhirst, M., Fan, T. M., Gustafson, D. L., Helman, L. J., Kastan, M. B., Knapp, D. W., Levin, W. J., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf0746 · Cited by 147

Non-immunoglobulin based protein scaffolds

Löfblom, J., Frejd, F. Y., & Ståhl, S. (2011) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2011.06.002 · Cited by 147

Enhancing Adoptive Cell Therapy of Cancer through Targeted Delivery of Small-Molecule Immunomodulators to Internalizing or Noninternalizing Receptors

Zheng, Y., Tang, L., Mabardi, L., Kumari, S., & Irvine, D. J. (2017) · ACS Nano · doi:10.1021/acsnano.7b00078 · Cited by 146

The role of mechanism-based pharmacokinetic–pharmacodynamic (PK–PD) modelling in translational research of biologics

Agoram, B. M., Martin, S. W., & van der Graaf, P. H. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2007.10.002 · Cited by 145

Correlating preclinical animal studies and human clinical trials of a multifunctional, polymeric nanoparticle

Eliasof, S. D., Lazarus, D. D., Peters, C. G., Case, R. I., Cole, R. O., Hwang, J., Schluep, T., Chao, J., Lin, J. L., Yen, Y., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1309566110 · Cited by 144

Immuno-imaging using nanobodies

Vaneycken, I., D’Huyvetter, M., Hernot, S., Vos, J. D., Xavier, C., Devoogdt, N., Caveliers, V., & Lahoutte, T. (2011) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2011.06.009 · Cited by 142

Challenges Associated and Approaches for Successful Translation of Nanomedicines Into Commercial Products

Agrahari, V., & Hiremath, P. S. (2017) · Nanomedicine · doi:10.2217/nnm-2017-0039 · Cited by 142

Combination antitumor therapy with targeted dual-nanomedicines

Dai, W., Wang, X., Song, G., Liu, T., He, B., Zhang, H., Wang, X., & Zhang, Q. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.03.001 · Cited by 140

High-throughput quantitation of inorganic nanoparticle biodistribution at the single-cell level using mass cytometry

Yang, Y.-S. S., Atukorale, P. U., Moynihan, K. D., Bekdemir, A., Rakhra, K., Tang, L., Stellacci, F., & Irvine, D. J. (2017) · Nature Communications · doi:10.1038/ncomms14069 · Cited by 138

Harnessing the Power of Nanotechnology for Enhanced Radiation Therapy

Goel, S., Ni, D., & Cai, W. (2017) · ACS Nano · doi:10.1021/acsnano.7b03675 · Cited by 132

Nanoengineered Templated Polymer Particles: Navigating the Biological Realm

Cui, J., Richardson, J. J., Björnmalm, M., Faria, M., & Caruso, F. (2016) · Accounts of Chemical Research · doi:10.1021/acs.accounts.6b00088 · Cited by 131

New insights into the pretargeting approach to image and treat tumours

Patra, M., Zarschler, K., Pietzsch, H., Stephan, H., & Gasser, G. (2016) · Chemical Society Reviews · doi:10.1039/c5cs00784d · Cited by 129

The Pharmacology of Monoclonal Antibodiesa

Weinstein, J. N., Eger, R. R., Covell, D. G., BLACK, C. D. V., Mulshine, J. L., Carrasquillo, J. A., Larson, S. M., & Keenan, A. M. (1987) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1987.tb45802.x · Cited by 127

Evaluation of nanomedicines: stick to the basics

McNeil, S. E. (2016) · Nature Reviews Materials · doi:10.1038/natrevmats.2016.73 · Cited by 126

A Phase I Trial of Humanized Monoclonal Antibody A33 in Patients with Colorectal Carcinoma: Biodistribution, Pharmacokinetics, and Quantitative Tumor Uptake

Scott, A. M., Lee, F.-T., Jones, R., Hopkins, W., MacGregor, D. P., Cebon, J. S., Hannah, A., Chong, G., Paul, U., Papenfuss, A. T., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2329 · Cited by 125

Cancer nanomedicine: Addressing the dark side of the enhanced permeability and retention effect

Huynh, E., & Zheng, G. (2015) · Nanomedicine · doi:10.2217/nnm.15.86 · Cited by 125

Bias in the reporting of sex and age in biomedical research on mouse models

Flórez-Vargas, O., Brass, A., Karystianis, G., Bramhall, M., Stevens, R., Cruickshank, S., & Nenadic, G. (2016) · eLife · doi:10.7554/elife.13615 · Cited by 124

Drug Delivery Research for the Future: Expanding the Nano Horizons and Beyond

Mitragotri, S., Lammers, T., Bae, Y. H., Schwendeman, S. P., Smedt, S. C. D., Leroux, J., Peer, D., Kwon, I. C., Harashima, H., Kikuchi, A., et al. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.01.011 · Cited by 124

Targeting tumor associated macrophages (TAMs) via nanocarriers

Singh, Y., Pawar, V. K., Meher, J. G., Raval, K., Kumar, A., Shrivastava, R., Bhadauria, S., & Chourasia, M. K. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.03.395 · Cited by 124

Engineering and evaluating drug delivery particles in microfluidic devices

Björnmalm, M., Yan, Y., & Caruso, F. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.04.030 · Cited by 123

Nanomedicine 2.0

Chan, W. C. W. (2017) · Accounts of Chemical Research · doi:10.1021/acs.accounts.6b00629 · Cited by 123

Phase 0 Clinical Trials: Conceptions and Misconceptions

Kummar, S., Rubinstein, L., Kinders, R. J., Parchment, R. E., Gutierrez, M. E., Murgo, A. J., Ji, J., Mroczkowski, B., Pickeral, O. K., Simpson, M., et al. (2008) · The Cancer Journal · doi:10.1097/ppo.0b013e318172d6f3 · Cited by 111

Biodistribution and Radiation Dosimetry of the Anti-HER2 Affibody Molecule 68Ga-ABY-025 in Breast Cancer Patients

Sandström, M., Lindskog, K., Velikyan, I., Wennborg, A., Feldwisch, J., Sandberg, D., Максимилианович, Т. В., Orlova, A., Sørensen, J., Carlsson, J., et al. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.169342 · Cited by 110

Targeting Tumor Microenvironment for Cancer Therapy

Roma-Rodrigues, C., Mendes, R., Baptista, P. V., & Fernandes, A. R. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20040840 · Cited by 1,187

Exploiting the dynamics of the EPR effect and strategies to improve the therapeutic effects of nanomedicines by using EPR effect enhancers

Fang, J., Islam, W., & Maeda, H. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.005 · Cited by 757

Minimum information reporting in bio–nano experimental literature

Faria, M., Björnmalm, M., Thurecht, K. J., Kent, S. J., Parton, R. G., Kavallaris, M., Johnston, A. P. R., Gooding, J. J., Corrie, S. R., Boyd, B. J., et al. (2018) · Nature Nanotechnology · doi:10.1038/s41565-018-0246-4 · Cited by 710

Overcoming the Blood–Brain Barrier: The Role of Nanomaterials in Treating Neurological Diseases

Furtado, D., Björnmalm, M., Ayton, S., Bush, A. I., Kempe, K., & Caruso, F. (2018) · Advanced Materials · doi:10.1002/adma.201801362 · Cited by 708

Overcoming the biological barriers in the tumor microenvironment for improving drug delivery and efficacy

Zhou, Y., Chen, X., Cao, J., & Gao, H. (2020) · Journal of Materials Chemistry B · doi:10.1039/d0tb00649a · Cited by 213